ArrowMark Colorado Holdings LLC Makes New $3.39 Million Investment in Septerna, Inc. (NASDAQ:SEPN)

ArrowMark Colorado Holdings LLC bought a new position in Septerna, Inc. (NASDAQ:SEPN - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 147,886 shares of the company's stock, valued at approximately $3,387,000. ArrowMark Colorado Holdings LLC owned about 0.33% of Septerna as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of SEPN. Tower Research Capital LLC TRC bought a new stake in Septerna in the fourth quarter worth about $25,000. New York State Common Retirement Fund acquired a new position in Septerna during the fourth quarter worth $32,000. Legal & General Group Plc acquired a new position in Septerna during the fourth quarter valued at approximately $42,000. Summit Investment Advisors Inc. bought a new position in shares of Septerna in the fourth quarter worth about $45,000. Finally, PNC Financial Services Group Inc. acquired a new position in Septerna during the 4th quarter valued at $61,000.

Septerna Trading Down 9.9 %

Shares of SEPN traded down $0.71 during mid-day trading on Tuesday, reaching $6.45. The company had a trading volume of 223,178 shares, compared to its average volume of 416,596. Septerna, Inc. has a twelve month low of $4.17 and a twelve month high of $28.99. The stock's 50-day moving average price is $6.14.

Septerna (NASDAQ:SEPN - Get Free Report) last issued its quarterly earnings data on Thursday, March 27th. The company reported ($0.64) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.69) by $0.05. The company had revenue of $0.21 million for the quarter, compared to the consensus estimate of $0.13 million. On average, sell-side analysts forecast that Septerna, Inc. will post -7.11 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on SEPN. Wells Fargo & Company decreased their price objective on Septerna from $14.00 to $11.00 and set an "equal weight" rating on the stock in a report on Friday, March 28th. Cantor Fitzgerald reiterated an "overweight" rating and set a $50.00 price target on shares of Septerna in a research note on Tuesday, February 11th.

Insider Activity at Septerna

In other news, Director Alan Ezekowitz acquired 41,355 shares of the company's stock in a transaction on Thursday, March 6th. The stock was purchased at an average cost of $6.00 per share, with a total value of $248,130.00. Following the acquisition, the director now owns 104,101 shares of the company's stock, valued at $624,606. This trade represents a 65.91 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Gil M. Labrucherie purchased 5,000 shares of Septerna stock in a transaction dated Friday, February 21st. The stock was bought at an average price of $5.85 per share, for a total transaction of $29,250.00. Following the completion of the transaction, the chief financial officer now directly owns 30,000 shares in the company, valued at $175,500. The trade was a 20.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders acquired 74,346 shares of company stock valued at $439,670 in the last three months.

Septerna Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.